Presented in partnership with BC Cancer Care The CML treatment landscape continues to evolve, with Treatment-Free Remission (TFR) becoming an increasingly important topic for patients and clinicians alike. The CML Society of Canada is proud to present this patient education and engagement event in partnership with BC Cancer Care. Together, we are committed to ensuring...Read More

Generic versions of most CML tyrosine kinase inhibitors (TKIs) are now available and widely used in Canada. This is an important development for patients and the healthcare system alike — generics can significantly reduce costs for provincial drug plans and private insurers, and in many cases improve patient access to treatment. This page explains what...Read More